Group 1 - The company, Long Cheng Financial (01225), expects a consolidated profit of approximately HKD 49 million for the first half of 2025, compared to a net loss of about HKD 35 million in the same period last year [1] - The profit is primarily attributed to a fair value gain of approximately HKD 5 million on financial assets measured at fair value through profit or loss, whereas the same period in 2024 recorded a fair value loss of about HKD 43 million on such assets [1] - Additionally, the company anticipates a reversal of financing costs of approximately HKD 23 million related to bond redemptions for the fiscal year ending June 30, 2025 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Lerado Financial Group Company Limited 隆成金融集團有限公司 本公告所載資料僅基於董事會對本集團截至二零二五年六月三十日止六個月之未 經審核綜合管理賬目及現有財務資料的初步評估，有關資料尚未經本公司核數師 或審核委員會審閱或確認。具體財務數據將根據上市規則於切實可行情況下盡快 於本公司截至二零二五年六月三十日止六個月之中期業績公告內披露。 1 本公司股東及潛在投資者於買賣本公司股份時務請審慎行事。 代表董事會 隆成金融集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：1225） 正面盈利預告 本公告乃由隆成金融集團有限公司（「本公司」，連同其附屬公司統稱「本集團」） 根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例 第571章證券及期貨條例（「證券及期貨條例」）第XIVA 部項下的內幕消息條文（定 義見上市規則）而刊發。 本公司 ...

格隆汇8月18日丨隆成金融(01225.HK)公布，公司将于2025年8月28日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及审议派发中期股息的建议（如 有）。 ...

Lerado Financial Group Company Limited 隆成金融集團有限公司 （於百慕達註冊成立之有限公司） （股份代號：1225） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 董事會會議日期 隆成金融集團有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣布，董事 會會議將於二零二五年八月二十八日（星期四）舉行，藉以（其中包括）批准本公 司及其附屬公司截至二零二五年六月三十日止六個月之中期業績，以及考慮派付 中期股息（如有）。 代表董事會 隆成金融集團有限公司 執行董事 何觀禮 香港，二零二五年八月十八日 於本公告日期，執行董事為陳俊傑先生、何觀禮女士及梁錦波先生；及獨立非執行 董事為余達志先生、楊海琿先生及林全智先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 隆成金融集團有限公司 呈交日期: 2025年8月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01225 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | | | 本月底結存 | | | 500,000,000,000 | HKD | | 0.01 | HKD | | 5,000,000, ...

Financial Performance - Revenue for the fiscal year 2024 was HKD 157,235,000, a decrease of approximately 17.8% from HKD 191,422,000 in 2023[6] - The pre-tax loss for 2024 was HKD (175,157,000), representing 111.4% of revenue, an improvement from 145.4% in 2023[6] - Medical product sales revenue was approximately HKD 72,200,000, a slight increase of 0.4% compared to the previous year[9] - Sales revenue from plastic toys decreased by approximately 37.9% to about HKD 4,500,000 due to intense market competition[9] - The company's consolidated revenue for the year ended December 31, 2024, was approximately HKD 157.2 million, a decrease of about 17.9% compared to HKD 191.4 million in 2023[33] - The gross profit margin for the year ended December 31, 2024, was approximately 62.5%, down 6.5 percentage points from 69.0% in the previous year[33] - The net loss for the year was HKD 174,286,000, an improvement from a net loss of HKD 279,395,000 in 2023, representing a 37.5% reduction in losses[147] - Total comprehensive expenses for the year amounted to HKD 178,997,000, compared to HKD 252,510,000 in 2023, reflecting a decrease of 29.1%[147] Asset and Equity Position - The total assets decreased to HKD 824,714,000 from HKD 1,377,016,000 in 2023[6] - The company's equity attributable to owners was HKD 249,626,000, down from HKD 428,581,000 in 2023[6] - The company's total assets decreased to HKD 754,717,000 from HKD 1,301,062,000, indicating a significant reduction in asset base[148] - The company's equity attributable to owners decreased to HKD 249,626,000 from HKD 428,581,000, a decline of 41.8%[150] Liquidity and Financial Ratios - The current ratio dropped to 1.5 from 6.7 in 2023, indicating a decline in liquidity[6] - The current ratio as of December 31, 2024, was approximately 1.5, compared to 3.0 on December 31, 2023[34] - The debt-to-equity ratio as of December 31, 2024, was approximately 145.7%, down from 172.7% in 2023[34] Credit Risk Management - The group aims to minimize credit risk in its lending operations through stringent internal policies and regular monitoring of loan repayments[14] - The company reported an impairment loss of HKD 156,300,000 for accounts receivable as of December 31, 2024[23] - The expected credit loss provision decreased due to improvements in borrowers' financial conditions, enhancing their ability to meet debt obligations[23] - The aging analysis of receivables showed that overdue loans amounted to HKD 494.2 million as of December 31, 2024, compared to HKD 37.9 million in 2023[31] - The company has implemented a debt recovery procedure for overdue loans, including sending demand letters and considering legal action if necessary[19] Operational and Administrative Expenses - The administrative expenses for the year were HKD 55.9 million, an increase of 60.2% from HKD 34.9 million in 2023, mainly due to higher employee costs[33] - The financing costs decreased by 46.1% to HKD 28.2 million from HKD 52.3 million in the previous year, primarily due to bond redemptions during the year[33] Corporate Governance - The board consists of three executive directors and three independent non-executive directors[52] - A total of five board meetings were held in the fiscal year ending December 31, 2024, to review and approve financial and operational performance[58] - All independent non-executive directors have confirmed their independence according to the listing rules[53] - The company has implemented mechanisms to ensure the board's independence and has reviewed their effectiveness for the fiscal year ending December 31, 2024[55] - The company provides comprehensive onboarding materials to new directors, covering their responsibilities and the company's business[59] Shareholder Communication and Transparency - The company emphasizes effective communication with shareholders to enhance investor relations and ensure transparency in disclosures[88][89] - The annual general meeting is scheduled for June 26, 2025, providing a platform for direct communication between the board and shareholders[88] - The company has established a website to provide the latest information on business operations, financial data, and corporate governance practices[94] Audit and Compliance - The audit committee consists of three independent non-executive directors, with Mr. Yu serving as the chairman, and held three meetings during the year[76][79] - The audit committee is responsible for reviewing the financial reporting process, internal control systems, and providing recommendations to the board[77][78] - The company paid HKD 700,000 for audit services to its external auditor for the year ending December 31, 2024, with no non-audit services provided[87] - The auditor's report indicates that the financial statements present a true and fair view of the company's financial position as of December 31, 2024[127] Financial Instruments and Reporting Standards - The company has adopted new and revised Hong Kong Financial Reporting Standards, which are expected to have no significant impact on the financial performance and position[161] - The consolidated financial statements must be prepared in accordance with the Hong Kong Financial Reporting Standards and the Hong Kong Companies Ordinance, ensuring a true and fair view[139] - Financial assets and liabilities are recognized when the company becomes a party to the contractual provisions of the instrument[197]

Financial Performance - For the fiscal year ending December 31, 2024, the total revenue decreased to HKD 157,235,000 from HKD 191,422,000, representing a decline of approximately 17.8% year-over-year[2] - Gross profit for the same period was HKD 98,344,000, down from HKD 131,994,000, indicating a decrease of about 25.3%[2] - The net loss for the year was HKD 174,286,000, compared to a net loss of HKD 279,395,000 in the previous year, reflecting an improvement of approximately 37.6%[2] - The total comprehensive loss for the year amounted to HKD 178,997,000, down from HKD 252,510,000, showing a reduction of about 29.1%[3] - The group reported a pre-tax loss of HKD 175,157,000 for the year ending December 31, 2024, compared to a pre-tax loss of HKD 278,243,000 for the previous year[17][19] - The company reported a net loss of HKD 174,244,000 for the year 2024, compared to a net loss of HKD 279,466,000 in 2023, representing a 37.6% improvement in losses year-over-year[30] - The group recorded a loss of approximately HKD 174,300,000 for the year ended December 31, 2024, compared to a loss of HKD 279,400,000 in 2023, primarily due to expected credit loss on receivables of approximately HKD 175,600,000[45] Revenue Breakdown - Revenue from medical products for the year 2024 was HKD 72,234,000, a slight increase from HKD 71,956,000 in 2023, while revenue from plastic toys decreased from HKD 7,224,000 to HKD 4,487,000[15] - Total revenue from customer contracts for 2024 was HKD 157,235,000, down from HKD 191,422,000 in 2023, representing a decrease of approximately 17.8%[15] - External revenue from Hong Kong decreased from HKD 112,244,000 in 2023 to HKD 99,872,000 in 2024, a decline of about 11.0%[22] - The group’s external revenue from Europe fell from HKD 62,017,000 in 2023 to HKD 46,723,000 in 2024, a decrease of approximately 24.7%[22] - The group’s external revenue from the United States decreased from HKD 7,462,000 in 2023 to HKD 4,435,000 in 2024, representing a decline of about 40.7%[22] Assets and Liabilities - Current assets decreased significantly to HKD 754,717,000 from HKD 1,301,062,000, a decline of approximately 42%[4] - Current liabilities increased to HKD 512,763,000 from HKD 427,560,000, representing an increase of about 19.9%[4] - The company's total equity decreased to HKD 249,252,000 from HKD 428,249,000, a decline of approximately 41.9%[5] - The total amount of trade and other receivables and prepayments decreased to HKD 115,420,000 in 2024 from HKD 150,596,000 in 2023, a decline of 23.3%[31] - The group’s cash and cash equivalents decreased by approximately HKD 36,700,000 to about HKD 91,100,000 as of December 31, 2024[46] Cost and Expenses - The company reported a significant reduction in financial costs, decreasing to HKD 28,178,000 from HKD 52,313,000, a drop of approximately 46.1%[2] - The company recorded a total employee benefit expense of HKD 23,203,000 in 2024, down from HKD 27,607,000 in 2023, a decrease of 16.1%[28] - The impairment loss on loans receivable was HKD 156,259,000 in 2024, a decrease from HKD 285,397,000 in 2023, marking a 45% reduction[28] Segment Performance - The group has three operating segments: medical products and plastic toys, securities brokerage and asset management services, and lending and other financial services[14] - The group’s total interest income from receivables decreased from HKD 108,954,000 in 2023 to HKD 76,607,000 in 2024, a decline of approximately 29.7%[15] - The group’s total segment performance showed losses across all segments, with the medical products and plastic toys segment reporting a loss of HKD 14,106,000 for 2024[17] Dividends and Governance - The company did not recommend a final dividend for the year ending December 31, 2024, consistent with the previous year[29] - The board does not recommend the payment of a final dividend for the year ending December 31, 2024 (2023: none) [53] - The company has adopted the Corporate Governance Code and has confirmed compliance throughout the year ending December 31, 2024 [61] - The audit committee, composed of three independent non-executive directors, has reviewed the accounting principles and discussed audit and financial reporting matters for the year ending December 31, 2024 [60] Future Outlook - The group plans to expand its financial services in Hong Kong and China, focusing on existing businesses and exploring potential investment opportunities[44] - The group has initiated the development of asset management services but has not generated any revenue from this segment due to a weak market and declining investor enthusiasm[42] Miscellaneous - The company has not disclosed any new product developments or market expansion strategies during the reporting period[6] - There have been no significant events after the year ending December 31, 2024, up to the date of this announcement [54] - The company and its subsidiaries have not purchased, sold, or redeemed any of the company's listed securities for the year ending December 31, 2024 [55] - As of December 31, 2024, there are no interests or short positions in shares or debentures of the company held by directors, supervisors, or key executives [56] - The major shareholder list as of December 31, 2024, shows Opus Platinum Growth Fund holding 18,000,000 shares, representing 7.82% of the issued share capital [58] - The company’s financial statements for the year ending December 31, 2024, are consistent with the preliminary announcement figures [62] - The annual report for the year ending December 31, 2024, will be published on the stock exchange and the company's website in due course [63] - The company has not been informed of any other relevant interests or short positions in the issued share capital as of December 31, 2024 [58]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 96,750,000, an increase of 21.2% compared to HKD 79,802,000 for the same period in 2023[2] - The net loss for the period was HKD 35,143,000, compared to a net loss of HKD 20,274,000 in the previous year, representing a 73.5% increase in losses[2] - The basic and diluted loss per share for the six months ended June 30, 2024, was HKD (15.26), compared to HKD (8.83) in 2023, indicating a worsening of 73.5%[4] - The company reported a total comprehensive expense of HKD 36,178,000 for the period, compared to HKD 15,607,000 in the previous year, an increase of 131.5%[3] - The company reported a loss of HKD 35,143,000 for the six months ended June 30, 2024, compared to a loss of HKD 20,338,000 for the same period in 2023, representing a 73% increase in losses[22] Revenue Breakdown - Medical products generated revenue of HKD 36,286,000, up from HKD 35,447,000, while plastic toys revenue slightly decreased to HKD 1,812,000 from HKD 1,852,000[15] - Interest income from loans and finance leases increased significantly to HKD 58,080,000, compared to HKD 42,306,000 in the previous year, reflecting a growth of 37.4%[15] - Revenue from medical products for the six months ended June 30, 2024, was approximately HKD 36,300,000, representing an increase of about 2.4% year-on-year[36] - Interest income from lending activities for the six months ended June 30, 2024, was approximately HKD 48,800,000, up from HKD 31,800,000 in 2023, accounting for about 50.4% of total revenue[37] Cash Flow and Assets - Cash generated from operating activities was HKD 105,666,000, significantly up from HKD 18,569,000 in the same period last year[9] - Cash and cash equivalents at the end of the period were HKD 132,573,000, up from HKD 127,822,000, reflecting a slight increase of 3.0%[9] - The company’s non-current assets totaled HKD 74,955,000, a decrease from HKD 75,954,000, indicating a decline of 1.3%[5] - Trade and other receivables totaled HKD 86,823,000 as of June 30, 2024, down from HKD 150,596,000 at the end of 2023, indicating a 42% decrease[23] - The company’s receivables from loans decreased to HKD 978,564,000 from HKD 1,049,055,000, reflecting a decline of approximately 7%[27] - Cash and cash equivalents increased by approximately HKD 4,800,000 to about HKD 132,600,000 as of June 30, 2024, compared to HKD 127,800,000 as of December 31, 2023[40] Liabilities and Expenses - Total assets decreased to HKD 1,164,973,000 from HKD 1,301,062,000, reflecting a decline of 10.5%[6] - Current liabilities remained stable at HKD 427,257,000, compared to HKD 427,560,000 in the previous year[6] - The total amount of trade payables increased to HKD 43,706,000 from HKD 20,994,000, marking a 108% rise[30] - The total tax expense for the six months was HKD 29,000, a significant decrease from HKD 1,024,000 in the same period last year[18] Segment Performance - The group reported a segment loss of HKD 6,742,000 in the medical products and plastic toys business, while the lending and other financial services segment achieved a profit of HKD 24,239,000[16] - The fair value changes of financial assets through profit or loss resulted in a loss of HKD 43,230,000, indicating challenges in the investment portfolio[16] - The fair value changes of financial assets through profit or loss resulted in a loss of approximately HKD 43,230,000, compared to a loss of HKD 15,374,000 in the previous year[20] Corporate Governance and Compliance - The company has complied with the corporate governance code throughout the six months ending June 30, 2024[55] - The audit committee, consisting of three independent non-executive directors, reviewed the accounting principles and discussed audit and financial reporting matters for the six months ending June 30, 2024[56] - All directors confirmed full compliance with the securities trading code during the six months ending June 30, 2024[57] Future Outlook and Strategy - The company continues to focus on expanding its medical products and financial services segments, which are key growth areas[12] - The company plans to expand its financial services in Hong Kong and China, focusing on lending, leasing, and securities brokerage, while also exploring potential investment opportunities[38] - The company has not adopted new accounting standards that are not yet effective, and expects no significant impact on performance or financial position[12] - The company anticipates that the adoption of new accounting standards will not have a significant financial impact on the group[12] Staffing and Dividends - The company employed a total of 159 staff as of June 30, 2024, with 146 based in China and the remainder in Hong Kong[46] - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the previous year[21] - The board of directors did not recommend the payment of an interim dividend for the six months ended June 30, 2024[47] Stock Options and Investments - No stock options were granted, exercised, lapsed, or cancelled under the 2022 stock option plan for the six months ending June 30, 2024[49] - As of June 30, 2024, there are no specific plans for significant investments or capital assets[50] - There were no major acquisitions or disposals during the six months ending June 30, 2024[50] - As of June 30, 2024, the number of stock options available for grant under the 2022 stock option plan is 23,032,241[49] Shareholding Structure - The major shareholder, Opus Platinum Growth Fund, holds 18,000,000 shares, representing 7.82% of the issued share capital[54] - Mr. Lai Shu-Hsun indirectly owns approximately 40.03% of the issued share capital of Opus Platinum Growth Fund[54] Events After Reporting Period - No significant events occurred after June 30, 2024, up to the report date[50]

Financial Performance - Revenue for the six months ended June 30, 2024, was HKD 96,750,000, an increase of 21.2% compared to HKD 79,802,000 for the same period in 2023[4] - The net loss for the period was HKD 35,143,000, compared to a net loss of HKD 20,274,000 in the previous year, representing an increase in loss of 73.5%[5] - Basic and diluted loss per share for the six months ended June 30, 2024, was HKD (15.26), compared to HKD (8.83) for the same period in 2023[6] - Total comprehensive expenses for the period amounted to HKD 36,178,000, compared to HKD 15,607,000 in the previous year, indicating a significant increase of 131.5%[5] - The company reported a net other losses of HKD (52,729,000) for the period, significantly higher than HKD (12,793,000) in the previous year, indicating a deterioration in financial performance[4] - The group reported a loss before tax of HKD 35,143, impacted by a fair value loss of HKD 43,230 on financial assets[18] - The company reported a pre-tax loss of HKD 20,274,000 for the six months ended June 30, 2024, compared to a pre-tax loss of HKD 5,557,000 in the previous year[19] - The fair value change of financial assets through profit or loss resulted in a loss of HKD 43,230,000 for the current period, compared to a loss of HKD 15,374,000 in the previous period[22] - The group recorded a loss of approximately HKD 35.1 million for the six months ended June 30, 2024, compared to a loss of HKD 19.3 million in 2023, primarily due to a fair value loss of HKD 43.2 million on financial assets[41] Revenue Breakdown - Revenue from medical products reached HKD 36,286, up from HKD 35,447 in the previous year, indicating a growth of approximately 2.4%[17] - The group’s revenue from the lending business and other financial services was HKD 48,755, contributing significantly to overall revenue[18] - Total revenue for the group was HKD 96,750, compared to HKD 79,802 in the previous year, reflecting a growth of 21.2%[17] - Sales revenue from medical products for the six months ended June 30, 2024, was approximately HKD 36.3 million, an increase of about 2.4% compared to the same period in 2023[38] - Sales revenue from plastic toys decreased by approximately 2.2% to about HKD 1.8 million, mainly due to a reduction in orders from Chinese customers[38] - Interest income from loans and financing leases for the six months ended June 30, 2024, was approximately HKD 48.8 million, representing about 50.4% of the total revenue, compared to HKD 31.8 million in 2023[39] Cash Flow and Assets - For the six months ended June 30, 2024, the net cash generated from operating activities was HKD 105,666, compared to HKD 18,569 for the same period in 2023, representing a significant increase[11] - The net cash used in investing activities was HKD 519, a significant improvement from a cash outflow of HKD 14,781 in the previous year[11] - The net cash used in financing activities was HKD 100,399, compared to HKD 12,427 in the same period last year, indicating increased financing activities[11] - The total cash and cash equivalents as of June 30, 2024, stood at HKD 132,573, down from HKD 171,140 in the previous year[11] - As of June 30, 2024, the group's cash and cash equivalents increased by approximately HKD 4.8 million to about HKD 132.6 million compared to HKD 127.8 million on December 31, 2023[42] - Current assets decreased to HKD 1,164,973,000 as of June 30, 2024, down from HKD 1,301,062,000 at the end of 2023, a decline of 10.5%[8] - Trade and other receivables totaled HKD 86,823,000 as of June 30, 2024, down from HKD 150,596,000 as of December 31, 2023[25] - The total amount of loans receivable as of June 30, 2024, was HKD 978,564,000, a decrease from HKD 1,049,055,000 as of December 31, 2023[29] - The company reported an expected credit loss provision of HKD 512,872,000 for loans receivable as of June 30, 2024, unchanged from the previous year[29] - The net current assets of the group were approximately HKD 737.7 million as of June 30, 2024, down from HKD 873.5 million in 2023, with a current ratio of about 2.7[42] Liabilities and Financial Management - Total liabilities as of June 30, 2024, were HKD 812,671,000, compared to HKD 949,456,000 at the end of 2023, reflecting a decrease of 14.4%[8] - The total amount of bonds payable as of June 30, 2024, was HKD 640.2 million, down from HKD 740.2 million as of December 31, 2023[34] - The group’s total liabilities decreased from HKD 740.2 million in 2023 to HKD 640.2 million as of June 30, 2024, resulting in a debt-to-equity ratio of approximately 163.3%[42] - The company’s financial expenses related to bonds amounted to HKD 13,361,000 for the current period, down from HKD 30,261,000 in the previous period[22] - Trade payables increased to HKD 43.7 million as of June 30, 2024, from HKD 21.0 million as of December 31, 2023[32] - The total trade payables from the medical products and plastic toys business amounted to HKD 25.7 million as of June 30, 2024, compared to HKD 13.2 million in 2023[33] Dividends and Investments - The company did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with no dividend in the previous year[23] - The board did not recommend the payment of an interim dividend for the six months ended June 30, 2024, consistent with the previous year[49] - There were no significant investments or capital asset plans as of June 30, 2024, and no major acquisitions or disposals during the reporting period[52] Future Plans and Risk Management - The company plans to expand its financial services in Hong Kong and China, focusing on existing businesses and exploring potential investment opportunities[40] - The group has not adopted new accounting standards that are expected to have a significant impact on its financial performance[14] - The group has no pledged assets as of June 30, 2024, maintaining a conservative financial management policy[44] - The group has not established any hedging policies to mitigate foreign exchange risks, although management will continue to assess these risks[45] - The group faced stock price risk due to investments in listed securities, with no current hedging policies in place[46] - As of June 30, 2024, there were no significant contingent liabilities reported by the company[47] Employee Information - The group employed a total of 159 employees as of June 30, 2024, with 146 based in China and the remainder in Hong Kong[48]

Revenue and Financial Performance - Revenue for 2023 was HKD 191,422,000, a decrease of approximately 12.3% from HKD 218,238,000 in 2022[7] - The group reported a loss of approximately HKD 279.4 million for the year ended December 31, 2023, compared to a loss of HKD 367.6 million in 2022, primarily due to impairment losses on receivables of approximately HKD 285.4 million[27] - The company reported a net loss of HKD 279,395,000 for 2023, compared to a net loss of HKD 367,637,000 in 2022, representing a 24% improvement[151] - Interest income decreased to HKD 111,143,000 in 2023 from HKD 124,126,000 in 2022, a decline of 10.5%[149] - The cost of goods sold was HKD 59,428,000, down from HKD 72,866,000 in the previous year, reflecting a reduction of 18.4%[149] - The company's total assets decreased to HKD 1,301,062,000 in 2023 from HKD 1,595,449,000 in 2022, a decline of 18.4%[153] - The company's total liabilities increased to HKD 872,813,000 in 2023 from HKD 803,582,000 in 2022, an increase of 8.6%[155] - The company's total equity decreased to HKD 428,249,000 in 2023 from HKD 680,759,000 in 2022, a decline of 37%[155] - The company reported a pre-tax loss of HKD 278,243,000 for the year ended December 31, 2023, compared to a loss of HKD 345,563,000 in the previous year, indicating an improvement of approximately 19.5%[159] Assets and Liabilities - The total assets of the company decreased to HKD 1,377,016,000 from HKD 1,682,653,000 in 2022[7] - The company's equity attributable to owners decreased to HKD 428,581,000 from HKD 681,162,000 in 2022[7] - The current ratio decreased to 6.7 from 8.0 in the previous year, indicating a decline in liquidity[7] - The debt ratio increased to 172.9% from 116.0% in 2022, indicating a significant rise in leverage[7] - The group's net current assets as of December 31, 2023, were approximately HKD 1,108 million, down from HKD 1,397.1 million as of December 31, 2022[29] Revenue Sources - Medical product sales revenue was approximately HKD 72,000,000, down 15.9% year-over-year due to overall economic decline[10] - Plastic toy sales revenue decreased by 2.6% to approximately HKD 7,200,000, primarily due to intense market competition[10] - The subsidiary, Beigelong Securities, generated revenue of HKD 3,300,000, a slight increase from HKD 3,200,000 in 2022, contributing 1.7% to total revenue[11] Corporate Governance - The board consists of three executive directors and three independent non-executive directors[49] - The company adheres to the corporate governance code as per the listing rules[44] - The board is responsible for overseeing the overall development of the company to enhance shareholder value[45] - The company has established various committees to delegate responsibilities for daily management and operations[45] - The company has a diversity policy for board members, which is reviewed annually by the nomination committee[63] Risk Management and Compliance - The company emphasizes compliance with applicable laws and regulations in its operations[46] - The board is responsible for maintaining adequate risk management and internal control systems to protect shareholder investments and company assets[81] - The company conducts regular reviews of its internal control systems to identify and manage potential risks[81] - The company has implemented a whistleblowing policy allowing employees and independent third parties to report suspected misconduct anonymously, with a zero-tolerance stance on corruption[83] Future Plans and Strategies - The company plans to develop asset management services and launch various funds to attract new investors, although no revenue was generated from this segment in 2023[11] - The company aims to expand its customer base by offering unsecured loans, which will optimize the risk-return balance of its loan portfolio[22] - The company plans to continue focusing on market expansion and new product development to enhance future performance[158] Shareholder Relations - The company emphasizes effective communication with shareholders to enhance investor relations and ensure transparency in financial reporting[88] - The company has reviewed the implementation of its shareholder communication policy and found it to be effective[89] - The company has updated its articles of association in accordance with changes to the listing rules, approved by shareholders at the annual general meeting on June 27, 2023[94] Audit and Financial Reporting - The financial statements have been prepared in accordance with the Hong Kong Financial Reporting Standards, reflecting a true and fair view of the group's financial position as of December 31, 2023[133] - The auditor's responsibility is to obtain reasonable assurance that the financial statements are free from material misstatement, whether due to fraud or error[144] - The audit committee has recommended the reappointment of the auditor, KPMG, at the upcoming annual general meeting[131] Market Engagement and Growth - Longcheng Financial Group reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the fiscal year 2023[200] - The company’s user base grew by 20%, now totaling 2 million active users, indicating strong market engagement[200] - Longcheng Financial Group expects a revenue growth forecast of 10-12% for the next fiscal year, driven by new product launches and market expansion strategies[200] - The company has invested HKD 300 million in research and development for new financial technologies, aiming to enhance user experience and operational efficiency[200]